Aurika Arsenovna Asanova

Dr. Aurika Arsenovna Asanova


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Endocrine Surgery
Verified
Journal Article
Open access
PDF file
DED. K. Erikenova
D. K. Erikenova
MBM. S. Berlovich
M. S. Berlovich
AAAurika Arsenovna Asanova
Aurika Arsenovna Asanova
IKI. V. Kim
I. V. Kim
VVV. V. Voskoboynikov
V. V. Voskoboynikov
SSS. S. Serzhenko
S. S. Serzhenko
Primary hyperparathyroidism (PHPT) is an endocrine disease that develops due to excessive production of parathyroid hormone (PTH) by the parathyroid glands (PTG). The only radical treatment for PHPT is surgical removal of the affected gland —parathyroidectomy. The success of the operation directly depends on accurate preoperative diagnosis and determination of the pathological gland’s location, which is the main difficulty. The parathyroid glands are typically found on the thyroid gland’s posterior surface; however, the anatomy of this area is very variable, and the glands can be found in the most unexpected places. A person can have between two and eight parathyroid glands, making the search much more difficult. The pathological gland can be either significantly enlarged or remain within normal sizes, which makes it indistinguishable from healthy glands at visual examination. All these factors make diagnosis difficult and increase the risk of unsuccessful surgery. If the affected gland cannot be detected and removed during surgery, the patient faces persistence of the disease with the preservation of all symptoms and health risks. The diagnostic method is choosen individually by an endocrinologist. It is important to remember that timely diagnosis and proper treatment of PHPT play a decisive role in the prognosis of the disease. This article describes a clinical case demonstrating a variant of the atypical anatomical location of the parathyroid adenoma in zone X, the peculiarity of which emphasizes the importance of imaging methods at the preoperative stage.

23 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ISIrina Stanoevich
Irina Stanoevich
AAAurika Arsenovna Asanova
Aurika Arsenovna Asanova
SVSvetlana Vorotnikova
Svetlana Vorotnikova
ABAndrey Belov
Andrey Belov
EGEkaterina Grezina
Ekaterina Grezina
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Background/Objectives: Acromegaly is a systemic connective tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess; yet, the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n = 33), healthy controls (n = 45), and adenomyosis without acromegaly (n = 44). Uterine body measurements were obtained by TAUS/TVUS; cervical biometry was performed transvaginally in all cases. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p-values non-significant). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical width, AP thickness, and volume, together with altered U:C indices, whereas cervical length did not differ, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This noninvasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.

30 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ISIrina Stanoevich
Irina Stanoevich
AAAurika Arsenovna Asanova
Aurika Arsenovna Asanova
SVSvetlana Vorotnikova
Svetlana Vorotnikova
ABAndrey Belov
Andrey Belov
EGEkaterina Grezina
Ekaterina Grezina
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Background/Objectives: Acromegaly is a systemic connective-tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess, yet the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n=33), healthy controls (n=45), and adenomyosis without acromegaly (n=44). Uterine body and cervical length, width, and anteroposterior (AP) dimensions were measured transvaginally/transabdominally. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p>0.1). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical dimensions and altered U:C indices, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This non-invasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.